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Abstract
Introduction and objective. Gestational diabetes mellitus (GDM) is a pregnancy complication which increases the risk for 
maternal and foetal complications during pregnancy, and also significantly increases the cardiovascular risk for women’s 
health in the postpartum. Current literature provides contradictory information on the role of adiponectin (AdipoQ) in 
the course of GDM. The aim of the study was to measure AdipoQ concentration in blood of women with GDM and to find 
correlations between this adipokine and clinical and biochemical parameters of the atherogenic risk.   
Material and methods. The GDM group included 50 women diagnosed with GDM between 24 – 28 weeks of gestation who 
underwent routine prenatal tests for GDM in compliance with the guidelines of the Polish Diabetes Association. All patients 
underwent clinical and laboratory evaluation at GDM diagnosis. Laboratory tests included serum AdipoQ concentration, 
fasting glucose and insulin, OGTT, lipid parameters, C-reactive protein and fibrinogen in serum.   
Results. The GDM group showed significantly elevated fasting glucose, insulin, HOMA-IR values, total cholesterol, LDL-
cholesterol and triglicerydes as compared with the control group (p<0.05). The atherogenic index, CRP, fibrinogen in women 
with GDM were significantly higher than in the control group (p<0.05). AdipoQ concentrations did not differ significantly 
between the groups during gestation (p=0.7054). No correlations, except with the neonatal weight (r= – 0.29, p<0.05), were 
found between AdipoQ and the studied parameters.   
Conclusions. Based on the conducted studies, it may be conclude that women with early diagnosed and promptly treated 
GDM have a normal adiponectin level, although insulin resistant changes and increased cardiovascular risk in basic metabolic 
parameters are observed. Moreover, adiponectin does not reflect the atherogenic risk in pregnant women with GDM.
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INTRODUCTION
Gestational diabetes mellitus (GDM) is any impaired 
carbohydrate tolerance (impaired fasting glucose, impaired 
glucose tolerance or diabetes) diagnosed during pregnancy 
[1]. Current data indicate that GDM is a slowly developing 
form of type 2 diabetes (T2DM) in the stage of increasing 
insulin resistance arising from the hormonal activity of 
the placenta. GDM usually subsides after pregnancy, but 
it remains a T2DM risk factor for the mother in the future 
as a woman once diagnosed with GDM has a sevenfold 
increased risk of developing T2DM [2]. In the light of the 
growing epidemic problem of T2DM incidence in developed 
countries, with accompanying obesity and insulin resistance, 
as well as a higher prevalence of GDM, which is a precursor 
of higher incidence of T2DM in the future, active and 
multidisciplinary search for markers of this disease in 
the population of young women diagnosed with GDM is 
necessary [3, 4]. Several studies have demonstrated evidence 
of the increased cardiovascular risk and higher prevalence of 
cardiovascular events later in life in the population of women 
with a history of GDM [5, 6, 7].
The key role of insulin resistance, which is the main 
pathogenic mechanism for obesity, T2DM and GDM, points 
to the need to find characteristic alterations in the factors that 
affect this phenomenon. It has been proved that adipokines, 
i.e. compounds secreted by the visceral adipose tissue, play 
a vital role in the regulation of insulin sensitivity in tissues 
[8]. Among many discovered adipokines, in recent years 
adiponectin (AdipoQ) has been an object of great interest. 
AdipoQ is the main adipokine of adipose tissue largely 
known for its insulin sensitizing properties [9]. It has been 
reported that low AdipoQ in serum correlates with increased 
insulin resistance, obesity and development of metabolic 
and cardiovascular disorders [10]. Furthermore, AdipoQ 
is involved in multiple physiological processes including 
energy metabolism, inflammation and vascular physiology, 
by acting directly in the liver, skeletal muscle, and vascular 
endothelium. A lot of research has revealed that AdipoQ also 
has anti-inflammatory, anti-atherogenic and cardioprotective 
effects [11, 12]. Decreased plasma AdipoQ levels are associated 
with atherosclerosis, low-grade metabolic inflammation and 
cardiovascular complications [12].
The data on AdipoQ concentration in GDM and future 
cardiovascular risk of women with prior history of GDM 
are contradictory. Therefore, the aim of the presented study 
was to measure AdipoQ concentration in blood of women 
with GDM, and to search for correlations of this adipokine 
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with selected clinical and biochemical parameters of the 
atherogenic risk.
MATERIAL AND METHODS
Patients. The study was conducted on pregnant women from 
the Lublin region who underwent routine prenatal tests 
for GDM in compliance with the guidelines of the Polish 
Diabetes Association [1]. The GDM group included 50 women 
diagnosed with GDM between 24 – 28 weeks of gestation. 
GDM was diagnosed with the use of a 75-gram glucose oral 
glucose tolerance test (OGTT), if, when 1 – 2 plasma glucose 
levels met or exceeded the following thresholds: fasting 
glucose concentration of 100 mg/dl and/or a 2-hour glucose 
concentration of 140 mg/dl. The control group comprised 
21 healthy pregnant women with normal OGTT results. 
The patients enrolled into the study gave written informed 
consent to participate and filled out a questionnaire which 
included the following information: patient’s age, height, 
pregestational weight, medical, family and obstetric history. 
The study protocol was accepted by the Bioethics Committee 
of the Medical University in Lublin.
Study design. All patients underwent clinical and laboratory 
evaluation at GDM diagnosis i.e. between 24 – 28 weeks of 
gestation. Anthropometric measurements were obtained 
from all participants. The weight was taken in light clothes 
and the height without shoes. Body mass index (BMI) was 
calculated according to the formula: weight (kg)/height (m2). 
Additionally, a retrospective analysis of anthropometric 
measurements was performed before gestation. Laboratory 
evaluation at GDM diagnosis included routine laboratory 
tests (fasting glucose, fasting insulin, C-reactive protein, 
fibrinogen, total cholesterol, HDL cholesterol and triglycerides 
in serum). AdipoQ concentration was measured in serum at 
GDM diagnosis.
The assays were performed with the use of a routine 
laboratory method with a biochemical analyzer ADVIA 
1650 with the Siemens’ Advia Chemistry reagent sets. The 
atherogenic index was calculated based on the concentration 
of triglycerides and HDL cholesterol [13]. An index above 0.5 
indicated an increased risk of cardiovascular complications. 
The LDL cholesterol concentration was calculated with the 
Friedewald equation [14]. Additionally, the indirect index 
of insulin resistance – HOMA-IR (Homeostasis Model 
Assessment – Insulin Resistance) was estimated [15]. Serum 
AdipoQ concentrations were measured with a commercial 
enzyme-linked immunosorbent assay kit: ‘Adiponectin 
Human ELISA’, Cat. No.: RD195023100 (BioVendor 
Laboratory Medicine, Modrice, Czech Republic), according 
to manufacturer’s instructions. The limit of detection 
was 26 ng/mL. The intra- and inter-assay coefficients of 
variation (CVs) were 4.9% and 6.7%, respectively. The results 
were read on a microtiter plate reader ELx 800 (Bio-Tek, 
USA). Laboratory analyses were carried out in the Central 
Laboratory of the Clinical Hospital No. 4 (SPSK4) and in 
the Department of Laboratory Diagnostics of the Medical 
University in Lublin.
Statistical analysis. Fisher’s exact test and Mann–Whitney 
test were employed to compare proportions and quantitative 
variables, respectively. Partial Spearman correlation 
coefficients between AdipoQ serum concentrations and 
other laboratory parameters were calculated. Results were 
expressed as median (interquartile range). All tests were 
considered significant with p<0.05. All analyses were 
performed with the MedCalc ver. 11.4.3.0.
RESULTS
Clinical characteristics of GDM and control groups. Table 1 
shows the clinical characteristics of the GDM and control 
groups. No significant differences were found between the 
groups in terms of the patients’ weight and BMI before and 
during pregnancy, i.e. at GDM diagnosis. The GDM group 
included more multipara women than the control group. 
No significant differences were found between the GDM 
and control groups in terms of neonatal weight and medical 
history concerning the number of miscarriages and diabetes 
in previous pregnancies. More patients had a family history 
of diabetes in the GDM than in the control group (Tab. 1).
Evaluation of adiponectin and metabolic parameters in 
GDM and control groups. Evaluation of glycaemia, insulin 
resistance and lipids in both groups is shown in Table 2. 
At GDM diagnosis, the GDM group showed significantly 
elevated fasting glucose and insulin levels HOMA-IR values, 
compared with the control group (p<0.05). In the lipid 
profile, significant changes were found in the GDM group 
during pregnancy, compared to the control group (p<0.05). 
What is more, the concentration of total, LDL cholesterol 
and triglycerides was higher while HDL cholesterol was 
significantly lower than in the healthy subjects (p<0.05). 
The atherogenic index, C-reactive protein and fibrinogen 
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Table 1. Clinical characteristics of GDM and control groups
Studied parameter GDM group  Control group 
Age (years) 31.0 (29.0-32.0) 29.0 (26.0-33.0)
Height (m) 1.63 (1.6-1.67) 1.64 (1.6-1.69)
Weight (kg)
before gestation 61.5 (58.0-66.0) 58.0 (54.7-61.7)
during gestation 71.0 (66.7-75.0) 69.0 (63.2-75.0)
BMI (kg/m2)
before gestation 23.0 (21.6-25.8) 21.6 (20.7-23.2)
during gestation 26.9 (24.8-30.0) 25.6 (24.0-28.1)
Pregnancy
first 20 (40%) * 15 (72%)
second 19 (38%) 4 (19%)
third and 
subsequent
11 (22%) 2 (9%)
Birth weight (g)
3205.0
        (3100.0-3650.0)
3300.0
(3245.0-3475.0)
Gestational age (weeks) 26.0 (25.0-28.0) 28.0 (24.0-28.0)
History of
miscarriage
no 31 (62%) 15 (72%)
one 15 (30%) 6 (28%)
two 4 (8%) 0 (0%)
History of 
GDM
no 43 (86%) 21 (100%)
yes 7 (14%) 0 (0%)
Family history 
of diabetes
no 22 (44%)* 18 (85.7%)
yes 28 (56%) 3 (14.3%)
Quantitative variables – median (interquartile range)
Qualitative variables – number of observations (percentage)
p < 0.05 in comparison with the control groupAnnals of Agricultural and Environmental Medicine 2014, Vol 21, No 1
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in women with GDM was significantly higher than in the 
control group (p<0.05).
No significant differences were found in terms of AdipoQ 
concentration in pregnancy between the groups. The median 
adiponectin concentrations with the interquartile range for 
the GDM and control groups were 15.8 (12.8–17.8) μg/ml and 
15.9 (10.4–18.4) μg/ml; p=0.7054, respectively.
Evaluation of correlations between adiponectin 
concentration and clinical features in the GDM and 
control groups. Tables 3 and 4 present correlations between 
adiponectin concentration and the studied parameters in 
the GDM and control groups. In the GDM group, AdipoQ 
concentration significantly negatively correlated with the 
neonatal weight (r=-0.29; p<0.05); no other correlations 
between the adiponectin concentration and the studied 
clinical features were found in the GDM and control groups 
(Tab. 3). In both groups during pregnancy, no significant 
correlations were observed between the concentration of 
AdipoQ and glycemia and HOMA-IR values. No differences 
were detected between the studied adipokine and the lipid 
parameters (Tab. 4).
DISCUSSION
Despite the fact that many authors have emphasized 
the multidirectional role of AdipoQ in obesity, T2DM, 
metabolic syndrome or GDM, especially the link 
between hypoadiponectinaemia and those disorders, 
pathophysiological implications of this adipokine have not 
yet been fully explained [16, 17, 18]. Diagnosed GDM not 
only increases the risk of maternal and foetal complications 
during pregnancy, but also significantly increases a 
woman’s risk of both T2DM and cardiovascular disease 
(CVD) in the postpartum. Even women with milder 
forms of abnormal glucose homeostasis during pregnancy, 
specifically gestational impaired glucose tolerance, are at 
increased risk, which justifies the recent recommendation 
to tighten the diagnostic criteria for GDM, thus including 
many more women. The factors that increase the risk of 
future CVD among women with a history of GDM include: 
postpartum progression to T2DM metabolic syndrome, 
obesity, hypertension, and altered levels of circulating 
inflammatory markers, particularly AdipoQ, dyslipidaemia, 
CRP, fibrinogen [19].
Current studies show that AdipoQ concentration in serum 
of women with GDM does not differ from its level in healthy 
pregnant subjects, which corroborates the findings of some 
authors [20, 21], but contradicts the results of others [22, 
23]. Thyfault et al. showed that AdipoQ concentration may 
depend on the severity of insulin resistance and carbohydrate 
metabolism disorder [23]. In the literature to-date, the results 
of AdipoQ determination are not clear. Some authors who 
showed hypoadiponectinaemia often demonstrated a slightly 
different metabolic phenotype of the population with GDM. 
Hypoadiponectinaemia significantly correlated with insulin 
resistance parameters and consequently with the severity of 
carbohydrate metabolism disorders [22, 24]. What is more, 
the authors of the Hyperglycaemia and Adverse Pregnancy 
Outcome (HAPO) Study also demonstrated depressed 
AdipoQ concentration with accompanying increased 
maternal glucose level [25].
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Table 2. Evaluation of metabolic parameters in the GDM and control 
groups at 24-28 week of gestation
Studied parameter GDM group  Control group 
Fasting glucose (mg/dl) 87.0 (79.0-93.0)* 78.0 (74.0-81.0)
Fasting insulin (mU/l) 10.9 (7.0-15.0)* 6.5 (5.4-7.3)
HOMA-IR 2.4 (1.9-3.5)* 1.2 (1.1-1.4)
glucose in OGTT 
(mg/dl)
0 min. 87.0 (79.0-93.0)* 78.0 (74.0-81.0)
120 min. 167.0 (156.0-189.0) -
Cholesterol (mg/dl) 268.0 (250.0-289.0)* 210.0 (194.5-230.7)
LDL cholesterol  (mg/dl) 150.1 (134.6-165.0)* 105.0 (91.5-113.0)
HDL cholesterol (mg/dl) 70.1 (65.0-76.0)* 80.0 (70.7-86.5)
Triglycerides (mg/dl) 245.0 (223.0-268.0)* 180.0 (167.25-198.5)
Atherogenic index 0.536 (0.506-0.595)* 0.350 (0.324-0.409)
C-reactive protein (mg/l) 4.0 (2.7-5.8)* 2.1 (1.2-3.0)
Fibrinogen (g/l) 4.8 (4.2-5.6)* 3.8 (3.5-5.2)
Adiponectin (ug/ml) 15.8 (12.8-17.8) 15.9 (10.4-18.4)
Quantitative variables – median (interquartile range) 
*   p < 0.05 in comparison with the control group
Table 4. Evaluation of the correlations between adiponectin 
concentration and metabolic parameters in the GDM and control groups 
during gestation in the Spearman’s rank correlation test
Studied parameter GDM group  Control group 
Fasting glucose (mg/dl)  0.065 –0.253
Fasting insulin (mU/l) –0.053 –0.213
HOMA-IR 0.053 –0.290
glucose in OGTT 
(mg/dl)
0 min. 0.065 –0.253
120 min. –0.040 –
Cholesterol (mg/dl) –0.124 0.319
LDL cholesterol  (mg/dl) –0.120 0.261
HDL cholesterol (mg/dl) –0.050 0.287
Triglycerides (mg/dl) –0.054  0.224
Atherogenic index –0.019 –0.061
C-reactive protein (mg/l) –0.124 –0.077
Fibrinogen (g/l) –0.039  0.335
Table 3. Evaluation of the correlations between adiponectin concentration 
and clinical features in the GDM and control groups
Studied parameter GDM group  Control group 
Age (years) –0.221  0.025
Height (m) 0.149 –0.286
Weight (kg) at 24-28 weeks 0.213 –0.043
BMI (kg/m2) at 24-28 weeks 0.015 0.095
Sequence of pregnancy –0.038 –0.208
Birth weight –0.290* –0.012
Week of gestation 0.070 0.053
History of miscarriage 0.057 –0.183
History of 
GDM
no 15.8 (12.8-17.9) –
yes 16.6 (13.2-16.9) –
Family history 
of diabetes
no 14.3 (11.9-16.9) –
yes 16.6 (13.9-18.4) –
With yes/no categories the Mann–Whitney U test was used to compare the values
* p < 0.05 in the Spearman’s rank correlationAnnals of Agricultural and Environmental Medicine 2014, Vol 21, No 1
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No clear-cut criteria, neither the diagnostic nor the 
treatment criteria, may underlie the discrepancy in the results 
of the studies from various parts of the globe, which means 
that the populations of GDM women are heterogeneous 
and metabolically incomparable. Retnakaran et al. revealed 
high heterogeneity of the group of IGT pregnant women as 
the patients with abnormal glucose level after one hour had 
metabolic features similar to those of the GDM patients, 
while after two and three hours the results were close to 
those of the healthy pregnant women [26]. Thus, it seems that 
the international unification of diagnostic criteria in GDM 
proposed by the International Association of the Diabetes 
and Pregnancy Study Groups (IADPSG), based on the results 
of the HAPO Study, could help make the populations of 
pregnant women with GDM more homogeneous in terms of 
metabolic markers, and therefore make the observations of 
researchers and the work of clinicians more efficient [27, 28].
The GDM group had typical biochemical disorders, 
especially in terms of impaired carbohydrate and lipid 
metabolism, as well as insulin sensitivity parameters, 
compared to healthy pregnant women. The observed changes 
most probably reflected already existing metabolic disorders 
which arose from GDM [29, 30]. In terms of the body weight, 
it was found that pregestational and gestational BMIs were 
comparable, which may suggest a similar growth of adipose 
tissue during pregnancy in both groups. This phenomenon 
may serve as an additional argument for the lack of 
differences between AdipoQ concentrations in pregnant 
women since a negative correlation between this adipokine 
and BMI has been suggested by other authors, including 
with regard to non-pregnant women [31, 32]. Carbohydrate 
metabolism disorders in women with GDM may be short-
term thanks to quick diagnosis and effective treatment. 
However, it seems that these types of disorders may not be 
reflected in AdipoQ concentrations or they may manifest 
themselves adequately to the severity of insulin resistance 
and carbohydrate metabolism disorders. Therefore, it 
should be stressed that a positive GDM diagnosis following 
the Polish guidelines translates into a quick therapeutic 
intervention, at first only with diet management or diet 
enriched with insulin to provide a normal maternal and 
foetal glucose levels. There have been many reports which 
confirm a strong correlation between hypoadiponectinaemia 
and insulin resistance in GDM [17, 21]. Insulin resistance 
determined with the rise in the HOMA-IR values in the GDM 
group, which most certainly was affected by higher glucose 
levels and fasting hyperinsulinaemia, did not correlate with 
AdipoQ concentrations or with the above parameters in the 
study group. Owecki et al. obtained comparable results from 
a group of obese adults [32]. However, it should be noted 
that HOMA-IR was only surrogate measurement and does 
not reflect the insulin resistance in full; it is also affected 
by measurement errors of glucose and insulin. Therefore, 
incorporating the direct technique of metabolic clamp, 
unavailable in our conditions, would be a better choice. 
Although the control and GDM groups had comparable 
BMIs, women in the latter group had a more atherogenic 
lipid profile and higher fasting plasma glucose, as well as 
insulin levels; thus, they seemed to be more insulin resistant. 
Research conducted by Carr DB et al. provides evidence that 
a history of GDM is associated with a higher prevalence of 
CVD in the population with a family history of diabetes. 
Furthermore, women with a history of GDM experienced 
cardiovascular events at a younger age compared with the 
women without a history of GDM [33]. In the GDM group in 
the presented study, higher fibrinogen levels were observed, 
in comparison to normal pregnancy, which may indicate 
increased cardiovascular risk in this group. The results 
of Ko at al. confirmed close correlations between plasma 
fibrinogen and cardiovascular risk factors, in particular 
abnormal lipid and glucose metabolism [34]. Increased 
CRP levels in GDM compared with healthy controls might 
indicate an increased risk of subclinical atherosclerosis and 
future atherosclerotic heart disease, which confirmed the 
findings of other researchers [35,36]. The data suggest that 
the high prevalence of impaired glucose levels and fasting 
hyperinsulinaemia, dyslipidaemia and altered inflammatory 
markers, with the exception of AdipoQ, make GDM a high-
risk situation for T2DM and CVD.
Finally, a negative correlation was noticed between 
maternal AdipoQ concentration and birth weight, which 
has been confirmed by the results of other parallel studies 
including ours [37, 38]. This may suggest an important role 
of maternal AdipoQ in birth weight control. If the rise in 
foetal AdipoQ level is also taken into consideration, the 
above correlation may point to two sources of adipose tissue 
development in the foetus and the newborn, and also to other 
disorders in adult life [38]. Nanda et al. proposed that AdipoQ 
concentration in early pregnancy, determined between 11 – 
13 weeks, could serve as a practical marker for predicting 
macrosomia in newborns [39].
The major limitation of the presented study is the quite small 
number of GDM subjects. However, it should be noted that 
the group of women recruited presented a typical phenotype 
for GDM, and it may be an argument that the results may be 
representative for GDM subjects, although the small number 
of women with gestational diabetes reflects a need for further 
research in this field in a large study population. Another 
issue is that for atherogenic risk assessment, only CRP, 
fibrinogen and lipid parameters were used, which may not 
allow for detailed evaluation of atherosclerotic processes. But 
what is important, these simple laboratory devices nowadays 
belong to routinely analyzed parameters in the laboratories 
and are available to physicians all over the world. Moreover, 
it should be stressed that these basic parameters may serve 
as tools for the assessment of atherogenic risk in a large 
population study.
In the light of contradictory findings about the role of 
AdipoQ in GDM and its predictive function in the incidence 
of DMT2 and CVD, there is a need for further and more 
detailed research in this field. It is necessary to find important 
mediators which play a role in insulin resistance pathogenesis 
whose analysis would allow us to comprehend the nature of 
the disorders underlying GDM.
CONCLUSIONS
Based on the conducted studies, it may be concluded that 
women with early diagnosed and promptly treated GDM 
have a normal adiponectin level, although insulin resistant 
changes and increased atherogenic risk in basic metabolic 
parameters, such as lipids, CRP and fibrinogen are observed. 
What is more, adiponectin does not reflect the atherogenic 
risk in pregnant women with GDM.
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